2026年11月3日星期二
M
Catatan Universal
Berita Kilat Global
Vietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei AsiaBangladesh turns to China for worker training amid graduate job struggles— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaOriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei AsiaVietnam solar success prompts rethink of power pricing— 日经 Nikkei AsiaGlobal legal body opens Hong Kong office, boosts city's law hub push— 日经 Nikkei AsiaWill Japanese insurers bring money home? 5 things to know— 日经 Nikkei AsiaChinese steel industry losses snowball as demand falls and costs rise— 日经 Nikkei AsiaSurging costs and China trade war test US farmers' loyalty to Trump— 日经 Nikkei AsiaBangladesh turns to China for worker training amid graduate job struggles— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaOriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei Asia

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Sumber Nature 医学研究4 hari lalu
Ringkasan konten

Situs ini hanya menyediakan indeks judul dan ringkasan, konten lengkap dan hak cipta sepenuhnya milik penerbit asli, silakan klik tautan asli untuk membaca.

Buka artikel asli
Saluran terkait
Kesehatan
Wilayah terkait
Perspektif global
Bahasa asli
English
Nomor entri
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · Catatan Universal